Background
Ewing’s sarcoma (ES)/primitive neuroectodermal tumor (PNET) is a small round cell tumor with simple sarcoma-specific genetic alterations resulting in
TET/FET family member and
ETS family member fusion proteins [
1]. Pathologists no longer categorize ES and PNET as different tumors because their genetic abnormalities overlap. Instead, they are termed the Ewing’s sarcoma family of tumors [
2,
3], together with the Askin tumor. ES/PNET are most commonly seen in patients younger than 20 years of age and are derived mainly from bone [
4]. The tumor has been discovered in most organs, including the pancreas, liver, adrenal gland, esophagus, and uterus [
5‐
11]. However, ES/PNET is extremely rare in the small bowel. Although it has been reported previously in this location [
12‐
17], none of these reports came from China. Here, we present the first reported case in China of primary ES/PNET in the ileum with EWS rearrangement.
Discussion
ES/PNET belongs to a family of tumors that harbor the
EWSR1-
ETS fusion protein, according to recent studies [
18]. It is the second most common pediatric sarcoma of bone. It most commonly arises from bone but can develop in extraskeletal sites [
19]. The
EWSR1 gene, together with several other genes, forms the TET family [
20]. Their motif of RNA binding activity enables the
EWSR1-
ETS fusion protein to regulate target genes as transcription factors [
21,
22]. Previous research provided evidence that mesenchymal stem cells may be candidate cells from which ES/PNET originate and that
EWSR1‐
FLI1 may be the sole initiating factor in the pathogenesis of these tumors [
20,
23]. Such expression results in cell transformation, with the subsequent emergence of tumors bearing the morphological and gene expression hallmarks of Ewing’s sarcoma [
24].
Gastroenterological ES/PNET is extremely rare. Here, we have summarized all previous publications of gastrointestinal ES/PNET in Table
1 [
7,
12,
13,
17,
25‐
49]. Among the 36 cases, 3 cases were derived from the esophagus, 9 from the stomach, 5 were of colorectal origin, and 19 arose from the small intestine. The patient gender ratio (female/male) was 22/14, and the ages ranged from 9 to 68 years. Thirty-one of 32 cases were positive for CD99 immunoreactivity. Fluorescent in situ hybridization or real-time PCR tests confirmed that most cases had the
EWSR1-
ETS fusion protein. Intriguingly, however, only 4 non-metastatic gastrointestinal ES/PNET cases were treated only by resection of the tumor. Follow-up of these cases suggested that the patients were relatively younger and had up to 20 months of disease-free survival. In the current case, the young patient also refused to take adjuvant chemo- or radiotherapy. To our delight, after the 10-month follow-up examination, the patient is currently alive and well, without any sign of recurrence.
Table 1
Review of reported cases of gastrointestinal ES/PNET
Esophagus | 44 | F | - | - | - | + | - | + | + | + | - | Cx | ND | Johnson AD et al. |
Esophagus | 56 | M | - | ND | - | + | ND | ND | ND | + | Lymph nodes | Sx + ImCx | ND | Maesawa C et al. |
Esophagus | 21 | M | ND | ND | - | - | - | ND | + | ND | - | Sx + Rx | ND | Kim SB et al. |
Gastric | 31 | F | ND | ND | - | + | ND | + | - | + | - | Sx + Rx | 3 years DFS | Khuri S et al. |
Gastric | 19 | M | ND | ND | ND | + | + | ND | ND | ND | - | Cx | ND | Aras M et al. |
Gastric | 41 | F | + | + | ND | + | + | ND | ND | + | Intra-peritoneal | Sx + Cx + Rx | Died 110 months after surgery | Inoue M et al. |
Gastric | 30 | M | - | - | - | + | ND | ND | ND | ND | - | Sx | 6 month DFS | Ankouz A er al |
Gastric | 14 | M | - | - | - | + | + | ND | ND | + | Liver | Sx + Cx | 24 months DFS | Czekalla R et al. |
Gastric | 55 | M | + | + | - | + | + | - | ND | + | Lymph nodes | Sx | 13 months DFS | Song JM et al. |
Gastric | 68 | M | - | ND | - | + | + | ND | ND | + | Liver | Sx + Cx | Died 13 months after diagnosis | Rafailidis S et al. |
Peri-gastric | 44 | F | - | - | - | + | + | ND | + | ND | - | Sx | 20 months DFS | Colovic RB et al. |
Gastric | 63 | F | ND | ND | ND | ND | ND | ND | + | + | - | Sx + Cx | ND | Maxwell AM er al |
Colorectal | 59 | M | ND | + | - | + | - | ND | ND | + | Peritoneal dissemination | Sx | Died 7 months after diagnosis | Kuwabara K et al. |
Colorectal | 24 | F | - | - | - | + | ND | ND | ND | + | - | Sx | 20 months DFS | Tokudome N et al. |
Colorectal | 17 | M | - | - | - | + | ND | ND | ND | + | - | Sx + Cx | 1 years DFS | Drut R er al |
Colorectal | 34 | F | ND | ND | - | + | ND | ND | ND | + | Liver | Sx + StemCx | 7 years DFS | Aboumarzouk OM et al. |
Colorectal | 53 | M | - | ND | - | + | ND | ND | ND | ND | - | Sx + Cx + Rx | Died 2 years after diagnosis | Vardy J et al. |
Small bowel | 21 | F | ND | - | + | + | ND | ND | ND | ND | - | Sx + Cx | 10 months DFS | Adair et al. |
Small bowel | 20 | F | ND | ND | ND | + | ND | ND | + | - | - | Sx + Cx | 18 months DFS | Kie et al. |
Small bowel | 13 | M | ND | - | + | + | ND | ND | + | ND | - | Sx | 1 years DFS | Sarangarajan etal |
Small bowel | 40 | M | ND | + | - | + | ND | ND | + | ND | Intra-peritoneal | Sx + Cx | Died with recurrence 5 months after diagnosis | Horie and Kato |
Small bowel | 14 | M | ND | - | + | + | ND | ND | + | + | - | Sx + Cx | 10 month DFS | Graham et al. |
Small bowel | 9 | F | - | - | + | ND | ND | ND | + | + | - | Sx + Cx | Died 25 months after diagnosis | Shek et al. |
Small bowel | 53 | F | ND | ND | ND | + | ND | ND | ND | ND | - | Sx | ND | Balasubram-anina et al. |
Small bowel | 63 | M | ND | ND | ND | + | + | ND | ND | ND | Adrenal glands + lymph nodes | Sx + Cx | ND | Kim et al. |
Small bowel | 44 | M | ND | ND | - | + | ND | ND | ND | ND | Intra-peritoneal | Sx + Cx | Died 13 months after diagnosis | Sethi and Smith |
Small bowel | 32 | M | ND | ND | ND | + | ND | + | + | ND | - | Sx + Cx | 6 months DFS | Rodarte Shade et al. |
Small bowel | 15 | F | ND | ND | ND | ND | ND | ND | + | + | - | Sx + Cx | ND | Vignail et al. |
Small bowel | 18 | M | ND | ND | ND | ND | ND | ND | ND | ND | - | Sx + Cx | ND | Boehm et al. |
Small bowel | 18 | M | + | + | + | + | + | + | + | + | Liver | Sx | Died 8 months after diagnosis | Milione M et al. |
Small bowel | 20 | M | + | + | + | + | + | + | + | + | Liver | Sx + Cx | Died 28 months after diagnosis | Milione M et al. |
Small bowel | 42 | M | + | + | + | + | + | + | + | + | - | Sx + Cx | Died 11 months after diagnosis | Milione M et al. |
Small bowel | 45 | M | + | + | + | + | + | + | + | + | - | Sx + Cx | Died 13 months after diagnosis | Milione M et al. |
Small bowel | 15 | F | + | + | + | + | + | + | + | + | - | Sx + Cx + Rx | 28 months DFS | Milione M et al. |
Small bowel | 57 | M | + | + | + | + | + | + | + | + | - | Lost | Lost | Milione M et al. |
Small bowel | 28 | F | + | + | + | + | - | - | + | + | Liver | Sx + Cx | 204 months DFS | Milione M et al. |
To date, the 5-year survival rate of localized ES/PNET is relatively high (65%-75%). However, the outcome for metastatic patients is usually poor (<30%), despite the use of chemo- and/or radiotherapy [
50]. Several studies have indicated that localized extraskeletal ES/PNET has a more favorable outcome than skeletal tumors [
51,
52]. The optimal management for localized ES/PNET is still debated. The National Comprehensive Cancer Network guidelines recommend that any ES/PNET should be treated with local treatment (surgery and/or radiotherapy) plus chemotherapy [
53]. Nevertheless, consistent with our findings in Table
1, others have suggested that complete surgery, if feasible, may be a better option for local disease considering the late side effects of high-dose radiotherapy especially for children [
52,
54]. Because small bowel ES/PNET is extremely rare and difficult to cure, our case will contribute to the understanding of the prognosis and determination of optimal management.
In the current case, the 16-year-old female patient was initially misdiagnosed with malignant GIST because of the clinical symptoms and imaging results. To differentiate among ES/PNET, malignant GIST, clear-cell sarcoma, and synovial sarcoma, immunohistochemistry, ultrastructure analysis and FISH tests were performed. Malignant GIST usually expresses CD117, Dog-1 and CD34, which were all negative in this case. Although both synovial sarcoma and ES/PNET could have genetic rearrangements, the regions of these translocations are quite different. In ES/PNET, Chr22
EWS-FLI or
EWS-FEV translocations are commonly reported [
16]. However, in synovial sarcoma,
SYT-SSX translocation is frequently observed [
55]. Clear-cell sarcoma could be ruled out by negative immunohistochemistry for HMB45, S-100 and Melan A. A previous study also indicated the necessity of distinguishing from an intraabdominal desmoplastic small round cell tumor (IDSRCT) by histological and immunohistochemical characteristics when ES/PNET occurs in the abdominal cavity [
13].
Previous demographic research has suggested that Ewing’s sarcoma is far less frequent in China than in the United States Caucasian population [
56]. However, whether this finding is related to genetic background differences remains to be studied. Two recent publications noted a difference in Ewing’s sarcoma occurrence between Caucasian and Hispanic populations [
57,
58]. However, they did not include a reason to explain this differences.
Conclusions
In conclusion, we have described for the first time a rare case of localized ES/PNET occurring in the small intestine in the Chinese population, as confirmed by ultrastructure and genetic analyses. This case, together with previous reports, has expanded the spectrum of tumors in the small intestine.
Acknowledgments
The authors thank Dr. Na Jia from the Department of Pathology, Beijing Cancer Hospital, for his expert technical assistance performing FISH analyses.